Clinical Trial Update: Phase 3 Crossover Trial of Two Formulations of Setmelanotide in Participants With Specific Gene Defects in the MC4R Pathway [Phase 3]

View source ↗

Summary

Rhythm Pharmaceuticals reports results from a Phase 3 crossover trial comparing two formulations of setmelanotide in participants with Bardet-Biedl Syndrome or …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bardet-biedl Syndrome
• Pomc Deficiency

Drugs mentioned

• IMCIVREE (setmelanotide)

Snippet

Sponsor: Rhythm Pharmaceuticals, Inc. | Conditions: Bardet-Biedl Syndrome, POMC Deficiency | Phase 3 | Status: COMPLETED | Results posted: 2024-11-26